Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction

The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with suspected acute coronary syndrome (ACS) who do not meet traditional ST-elevation myocardial infarction (STEMI) criteria. The main questions it aims to answer are: 1. Does AI-assisted ECG interpretation enable more timely identification and treatment of OMI, as defined by earlier initiation of coronary intervention? 2. Does AI-assisted diagnosis reduce infarct size, measured by peak high-sensitivity troponin T (hsTnT) levels? Researchers will compare AI-assisted ECG interpretation to standard care to determine if the AI tool improves clinical outcomes and care timelines. Participants will: 1. Present with symptoms suggestive of ACS but without clear STEMI criteria 2. Be randomized 1:1 to either AI-assisted or standard ECG interpretation 3. Undergo follow-up assessments for cardiovascular outcomes, including 30-day death, time to treatment of total coronary occlusion, and peak hsTnT levels

NCT Number	NCT07077057
Lead Sponsor	Cardiocentro Ticino
Conditions	Myocardial Infarction (MI), Acute Coronary Syndrome (ACS)
Enrollment	500 participants
Start Date	2025-08-23
Primary Completion	2027-08 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-05